Assays for determining plasma kallikrein system biomarkers
JP7668772B2Active Publication Date: 2025-04-25TAKEDA PHARMA CO LTD
View PDF 0 Cites 0 Cited by
Patent Information
- Application Number
- JP2022137393
- Authority / Receiving Office
- JP · JP
- Patent Type
- Patents
- Current Assignee / Owner
- Priority Date
- 2014-02-14
- Filing Date
- 2022-08-31
- Publication Date
- 2025-04-25
- Estimated Expiration
- 2034-10-17
AI Technical Summary
Benefits of technology
【0039】 本開示の一つもしくはそれ以上の実施態様の詳細は、以下の説明において説明される。本開示の他の特徴もしくは利点は、以下の図および、いくつかの実施態様の詳細な説明、ならびに添付した特許請求の範囲から明らかになるであろう。
✦ Generated by Eureka AI based on patent content.
Smart Images
Figure 00000049_0000 
Figure 00000049_0001 
Figure 00000050_0000
Abstract
Methods and assays for determining the activation level of the plasma kallikrein (pKal) system and their use to assess the activity of pKal modulators on the pKal system are provided. [Solution] The present invention features an ex vivo activation method, which includes (i) incubating a plasma sample obtained from a subject with an activator of the plasma kallikrein (pKal) system (e.g., factor XIIa (FXIIa)), (ii) measuring the concentration of intact high molecular weight kininogen (HMWK), cleaved HMWK, or both, in the plasma sample before and after incubation, and (iii) determining the reduction of intact HMWK in the sample after activation.
Need to check novelty before this filing date? Find Prior Art
Claims
[Claim 1] An invention substantially as described in the specification or drawings.